Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Becotatug Vedotin (Anti-EGFR ADC) Combined With Pucotenlimab (Anti-PD-1) in Patients With Resectable Recurrent Head and Neck Squamous Cell Carcinoma Who Progressed on Prior PD-1/PD-L1 Inhibitor and Platinum-Based Therapy: A Prospective, Single-Arm, Multi-Center, Phase II Clinical Trial

NCT07589049 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07589049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07589049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Becotatug Vedotin (Anti-EGFR ADC) Combined With Pucotenlimab (Anti-PD-1) in Patients With Resectable Recurrent Head and Neck Squamous Cell Carcinoma Who Progressed on Prior PD-1/PD-L1 Inhibitor and Platinum-Based Therapy: A Prospective, Single-Arm, Multi-Center, Phase II Clinical Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
May 31, 2029
Enrollment
42 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma